Nature Communications (Jul 2022)

SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model

  • Carolin M. Lieber,
  • Robert M. Cox,
  • Julien Sourimant,
  • Josef D. Wolf,
  • Kate Juergens,
  • Quynh Phung,
  • Manohar T. Saindane,
  • Meghan K. Smith,
  • Zachary M. Sticher,
  • Alexander A. Kalykhalov,
  • Michael G. Natchus,
  • George R. Painter,
  • Kaori Sakamoto,
  • Alexander L. Greninger,
  • Richard K. Plemper

DOI
https://doi.org/10.1038/s41467-022-32045-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned. Here the authors evaluate molnupiravir against variant of concern in numerous models, including human airway epithelium organoids, ferrets and Roborovski dwarf hamsters.